Innovation Pays: Priority Drugs Drove Novel 2011 Approvals To New Heights
By
Bridget Silverman / Email the Author / Pharmaceutical Approvals Monthly January 2012, Vol. 17, No. 1
New Drug Approvals / Word Count: 2031 / Article # 06111201041
Executive Summary
The new molecular entity and novel biologic class of 2011 isn’t just the largest since 2004 – CDER also posted near-perfect on-time review performance while maintaining healthy rates of first-cycle approvals and a low 15 month average time to approval, thanks to a high level of innovation in the novel product candidates.
$85.00
Buy Now
For $85.00, purchase this 2031-word article and receive immediate online access. 100% Satisfaction Guarantee.
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.